Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name TP53 wild-type
Gene Variant Detail

TP53 wild-type (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04669067 Phase Ib/II KRT-232 + TL-895 TL-895 and KRT-232 Study in Acute Myeloid Leukemia Active, not recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT03725436 Phase I ALRN-6924 + Paclitaxel ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Active, not recruiting USA 0
NCT03940352 Phase I Siremadlin + Venetoclax Sabatolimab + Siremadlin HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Terminated USA | ITA | FIN | ESP | DEU | AUS 1
NCT01760525 Phase I CGM097 A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors Completed USA | FRA | DEU | CHE 1
NCT04835584 Phase Ib/II Dasatinib + KRT-232 KRT-232 + Nilotinib KRT-232 and TKI Study in Chronic Myeloid Leukemia Recruiting USA | POL | ITA | FRA | ESP | CAN 2
NCT06084689 Phase II BI 907828 + Ezabenlimab Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) Not yet recruiting FRA 0
NCT03560882 Phase I Atorvastatin A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Active, not recruiting USA 0
NCT03107780 Phase I KRT-232 Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Suspended USA 0
NCT03714958 Phase I Siremadlin + Trametinib Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) Completed FRA 0
NCT02842125 Phase I Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Terminated USA 0
NCT04190550 Phase I Cytarabine + Idarubicin + KRT-232 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Completed USA 0
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed USA 0
NCT03041688 Phase I Decitabine + KRT-232 + Venetoclax Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT01914900 Phase II Cisplatin + Docetaxel + Fluorouracil Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Completed ITA 0
NCT04502394 Phase Ib/II Acalabrutinib + KRT-232 Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL Unknown status USA | POL | ITA | GBR | FRA | CZE | CHE | BEL | AUS 2
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Active, not recruiting USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT02264613 Phase Ib/II ALRN-6924 Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors Completed USA 0
NCT04116541 Phase II Alectinib Cabozantinib Ribociclib + Siremadlin A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) Recruiting FRA 0
NCT03975387 Phase Ib/II ASTX295 Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 Active, not recruiting USA 0
NCT05797831 Phase II KRT-232 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Recruiting USA | SWE | SVN | ROU | POL | NOR | LTU | ITA | ISR | HUN | FIN | EST | ESP | DNK | CAN | AUT 1
NCT02143635 Phase I Siremadlin Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Completed USA | NLD | FRA | ESP | DEU 3